Evidence map›Paper›PMID 34376212›Full record

ArticleCancer cell international2021

Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression.

Yao Li, Yan Zhang, Xufang Wang, Qian Yang, Xuanxuan Zhou, Junsheng Wu, Xu Yang, Yani Zhao, Rui Lin, Yanhua Xie and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Yao Li *Faculty of Life Science & Medicine, Key Laboratory Resource Biology & Biotechnology in Western China, Ministry of Education, Northwest University, Xi'an, 710069, Shaanxi, China.
Yan Zhang *Department of Acupuncture, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, 710021, Shaanxi, China.
Xufang WangFaculty of Life Science & Medicine, Key Laboratory Resource Biology & Biotechnology in Western China, Ministry of Education, Northwest University, Xi'an, 710069, Shaanxi, China.
Qian YangDepartment of Chinese Materia Medica and Natural Medicines, Air Force Medical University, Xi'an, 710032, Shaanxi, China.
Xuanxuan ZhouDepartment of Chinese Materia Medica and Natural Medicines, Air Force Medical University, Xi'an, 710032, Shaanxi, China.
Junsheng WuFaculty of Life Science & Medicine, Key Laboratory Resource Biology & Biotechnology in Western China, Ministry of Education, Northwest University, Xi'an, 710069, Shaanxi, China.
Xu YangFaculty of Life Science & Medicine, Key Laboratory Resource Biology & Biotechnology in Western China, Ministry of Education, Northwest University, Xi'an, 710069, Shaanxi, China.
Yani ZhaoDepartment of Acupuncture, Xi'an Hospital of Traditional Chinese Medicine, Xi'an, 710021, Shaanxi, China.
Rui LinDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Yanhua XieFaculty of Life Science & Medicine, Key Laboratory Resource Biology & Biotechnology in Western China, Ministry of Education, Northwest University, Xi'an, 710069, Shaanxi, China.
Jiani YuanAir Force Hospital of Western Theater Command, Chengdu, 610083, Sichuan, China. 419655632@qq.com.
Xiaohui ZhengFaculty of Life Science & Medicine, Key Laboratory Resource Biology & Biotechnology in Western China, Ministry of Education, Northwest University, Xi'an, 710069, Shaanxi, China. zhengxh318@nwu.edu.cn.
Siwang WangFaculty of Life Science & Medicine, Key Laboratory Resource Biology & Biotechnology in Western China, Ministry of Education, Northwest University, Xi'an, 710069, Shaanxi, China. wangsiw@nwu.edu.cn.ORCID http://orcid.org/0000-0003-1888-4716
Ministry of Education of the People's Republic of China · CNAir Force Engineering University · CNShaanxi Provincial Hospital of Traditional Chinese Medicine · CNCommand Hospital Air Force · INXijing Hospital · CN

Funding

Science and Technology Innovation Project of Shaanxi province in China 2015SF2-08-01Shaanxi Key Laboratory of Biomedicine 2018SZS41Social Development of Shaanxi Province Key Project 2017ZDXM-SF-019Social Development of Shaanxi Province Key Project S2018-ZC-GCZXXY-SF-0005
6 · The paper itself

Abstract

backgroundGlioma is a common primary central nervous system tumour, and therapeutic drugs that can effectively improve the survival rate of patients in the clinic are lacking. Bufalin is effective in treating various tumours, but the mechanism by which it promotes the apoptosis of glioma cells is unclear. The aim of this study was to investigate the drug targets of bufalin in glioma cells and to clarify the apoptotic mechanism.

methodsCell viability and proliferation were evaluated by CCK-8 and colony formation assays. Then, the cell cycle and apoptosis, intracellular ion homeostasis, oxidative stress levels and mitochondrial damage were assessed after bufalin treatment. DARTS-PAGE technology was employed and LC-MS/MS was performed to explore the drug targets of bufalin in U251 cells. Molecular docking and western blotting were performed to identify potential targets. siRNA targeting Annexin A2 and the DRP1 protein inhibitor Mdivi-1 were used to confirm the targets of bufalin.

resultsBufalin upregulated the expression of cytochrome C, cleaved caspase 3, p-Chk1 and p-p53 proteins to induce U251 cell apoptosis and cycle arrest in the S phase. Bufalin also induced oxidative stress in U251 cells, destroyed intracellular ion homeostasis, and caused mitochondrial damage. The expression of mitochondrial division-/fusion-related proteins in U251 cells was abnormal, the Annexin A2 and DRP1 proteins were translocated from the cytoplasm to mitochondria, and the MFN2 protein was released from mitochondria into the cytoplasm after bufalin treatment, disrupting the mitochondrial division/fusion balance in U251 cells.

conclusionsOur research indicated that bufalin can cause Annexin A2 and DRP1 oligomerization on the surface of mitochondria and disrupt the mitochondrial division/fusion balance to induce U251 cell apoptosis.

Indexed as

Annexin A2BufalinDARTS-PAGE technologyDRP1Glioma cellMitochondrial dysfunction

Identifiers

PMID34376212
PMCPMC8353806
OpenAlexW3193243842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.